SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.
Fourth Quarter and Full Year 2024 Financial Results
About Kronos Bio
Kronos Bio is a biopharmaceutical company that has historically focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. In November 2024, we announced a process to evaluate potential strategic alternatives focused on maximizing stockholder value, including, but not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets, or other strategic transactions. Our activities to evaluate and pursue potential strategic alternatives may not result in any transaction or enhance stockholder value. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com or follow the Company on LinkedIn.
| Kronos Bio, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except per share data) (Unaudited) | |||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| Revenue | $ | 2,270 | $ | 2,286 | $ | 9,848 | $ | 6,288 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 8,409 | 18,704 | 48,664 | 84,515 | |||||||||||||
| General and administrative | 4,924 | 9,213 | 24,616 | 38,974 | |||||||||||||
| Impairment of long-lived assets and restructuring | 16,091 | 1,960 | 29,455 | 4,876 | |||||||||||||
| Total operating expenses | 29,424 | 29,877 | 102,735 | 128,365 | |||||||||||||
| Loss from operations | (27,154 | ) | (27,591 | ) | (92,887 | ) | (122,077 | ) | |||||||||
| Other income (expense), net: | |||||||||||||||||
| Interest income and other expense, net | 1,341 | 2,271 | 6,808 | 9,404 | |||||||||||||
| Total other income (expense), net | 1,341 | 2,271 | 6,808 | 9,404 | |||||||||||||
| Net loss | (25,813 | ) | (25,320 | ) | (86,079 | ) | (112,673 | ) | |||||||||
| Other comprehensive income (loss): | |||||||||||||||||
| Net unrealized gain (loss) on available-for-sale securities | (15 | ) | 274 | (10 | ) | 811 | |||||||||||
| Net comprehensive loss | $ | (25,828 | ) | $ | (25,046 | ) | $ | (86,089 | ) | $ | (111,862 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.43 | ) | $ | (0.43 | ) | $ | (1.43 | ) | $ | (1.95 | ) | |||||
| Weighted-average number of shares used to compute net loss per share, basic and diluted | 60,344 | 58,268 | 60,070 | 57,744 | |||||||||||||
| Kronos Bio, Inc. Selected Balance Sheet Data (in thousands) (Unaudited) | |||||
| December 31, 2024 | December 31, 2023 | ||||
| Cash, cash equivalents and investments | $ | 112,422 | $ | 174,986 | |
| Total assets | $ | 124,363 | $ | 213,279 | |
| Total liabilities | $ | 36,783 | $ | 54,201 | |
| Total stockholders’ equity | $ | 87,580 | $ | 159,078 | |
| Last Trade: | US$0.90 |
| Daily Change: | -0.04 -4.00 |
| Daily Volume: | 224,368 |
| Market Cap: | US$54.000M |
November 27, 2024 November 14, 2024 November 13, 2024 November 05, 2024 October 23, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
